4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
Published online 9 April 2008
Haematologica, Vol 93, Issue 6, 930-933 doi:10.3324/haematol.12206
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zaja, F.
Right arrow Articles by Fanin, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zaja, F.
Right arrow Articles by Fanin, R.

Brief Report

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

Francesco Zaja1, Marta Lisa Battista1, Maria Teresa Pirrotta2, Salvatore Palmieri3, Michela Montagna4, Nicola Vianelli5, Luciana Marin1, Margherita Cavallin1, Monica Bocchia2, Marzia Defina2, Micaela Ippoliti2, Felicetto Ferrara3, Francesca Patriarca1, Maria Antonietta Avanzini4, Mario Regazzi4, Michele Baccarani5, Miriam Isola6, Franca Soldano6, Renato Fanin1

1 Clinica Ematologica, DIRM, Azienda Ospedaliera Universitaria, Udine;
2 Clinica Ematologica, Policlinico Le Scotte, Siena;
3 Divisione di Ematologia, AORN "A. Cardarelli", Napoli;
4 Dipartimento di Farmacologia, Fondazione IRCCS Policlinico San Matteo, Pavia;
5 Istituto di Ematologia ed Oncologia Medica L. ed A. Seragnoli, Bologna and
6 Cattedra di Statistica, DIRM, Università di Udine, Italy

Correspondence: Francesco Zaja, M.D., Clinica Ematologica, Azienda Ospedaliera Universitaria, piazza S. Maria della Misericordia, 33100 Udine, Italy. E-mail:zaja.francesco{at}aoud.sanita.fvg.it

ABSTRACT

Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50x109/L) and complete responses (platelet count > 100x109/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3–18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.

Key words: immune thrombocytopenia, B-cell depletion, lower dose rituximab.




This article has been cited by other articles:


Home page
 BloodHome page
D. Provan, R. Stasi, A. C. Newland, V. S. Blanchette, P. Bolton-Maggs, J. B. Bussel, B. H. Chong, D. B. Cines, T. B. Gernsheimer, B. Godeau, et al.
International consensus report on the investigation and management of primary immune thrombocytopenia
Blood, January 14, 2010; 115(2): 168 - 186.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
W J Zheng, X Zhang, Q Wang, D Xu, X F Zeng, and F C Zhang
Refractory severe connective tissue disease thrombocytopenia: is rituximab treatment effective and safe?
Ann Rheum Dis, June 1, 2009; 68(6): 1077 - 1078.
[Full Text] [PDF]

Home page
 haematolHome page
K. Kelly, M. Gleeson, and P. T. Murphy
Slow responses to standard dose rituximab in immune thrombocytopenic purpura
Haematologica, March 1, 2009; 94(3): 443 - 444.
[Full Text] [PDF]

Home page
 haematolHome page
F. Zaja and R. Fanin
Slow responses to standard dose rituximab in immune thrombocytopenic purpura. Author reply
Haematologica, March 1, 2009; 94(3): 444 - 445.
[Full Text] [PDF]